Saturday 17 October 2026
Export HBIO’s income statement to Excel — free account
Harvard Bioscience, Inc.
HBIO Healthcare Medical Instruments & Supplies
Harvard Bioscience, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $86.6 million, down 8.06% from fiscal 2024. In the quarter to June 2026, revenue grew 11.1%, EPS fell 28.0%, free cash flow fell 123.4% and total debt rose 5.21%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
8.09
0.22
−2.65%
Follow HBIO
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.22 | 0.34 | 0.25 | 0.32 | |
P/FCF ratio |
2.87 | 6.11 | 17.01 | 0.00 | |
P/Operating CF |
18.09 | (309.81) | (32.91) | 85.65 | |
P/B ratio |
1.39 | 2.17 | 2.17 | 3.75 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.93 | 1.05 | 0.99 | 1.05 | |
EV/EBITDA |
16.80 | 13.70 | 11.80 | 13.00 | |
EV/Operating CF |
9.47 | 13.52 | 27.54 | 141.29 | |
EV/FCF |
11.88 | 18.69 | 66.25 | (50.21) | |
Quick Ratio |
0.35 | 1.12 | 0.91 | 0.85 | |
Current Ratio |
0.81 | 2.20 | 1.99 | 1.87 | |
Net Debt/EBITDA |
14.46 | 7.40 | 46.81 | 33.76 | |
Debt/Assets |
43.55% | 44.80% | 46.46% | 48.08% | |
Debt/Equity |
2.41 | 2.61 | 3.60 | 4.95 | |
Asset Turnover |
0.84 | 0.84 | 1.08 | 1.12 | |
Operating CF/Net income |
(0.88) | 0.03 | 0.19 | (0.11) | |
Capex/Depreciation |
(0.21) | (0.30) | (0.35) | (0.49) | |
Interest Coverage |
0.20 | 0.85 | (0.68) | (0.55) | |
Research and Development Expense of Revenue |
10.35% | 9.20% | 11.21% | 10.79% | |
Selling, General and Administrative Expense of Revenue |
42.68% | 38.81% | 48.36% | 44.08% | |
Intangible Assets out of Total Assets |
0.23 | 0.21 | 0.21 | 0.20 | |
Share Based Compensation of Revenue |
1.57% | 1.93% | 1.24% | 1.67% | |
Graham Net Nets |
(1.03) | (0.61) | (0.94) | (0.80) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(277.27%) | (191.04%) | (44.56%) | (37.56%) | |
Free Cash Flow Yield |
34.79% | 16.36% | 5.88% | (6.58%) | |
Revenue per Share |
4.62 | 5.35 | 4.64 | 5.02 | |
Operating CF per Share |
0.24 | (0.02) | (0.15) | 0.07 | |
Capex per Share |
(0.08) | (0.13) | (0.14) | (0.20) | |
Free Cash Flow per Share |
0.17 | (0.16) | (0.29) | (0.13) | |
Cash per Share |
1.53 | 1.94 | 1.59 | 1.44 | |
Shareholders Equity per Share |
3.16 | 3.09 | 2.25 | 1.64 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.16 | 3.09 | 2.25 | 1.64 | |
Free Cash Flow |
0.74 | (0.69) | (1.28) | (0.59) | |
Working Capital |
(10.59) | 26.27 | 23.62 | 21.67 | |
Capital Expenditures |
(0.35) | (0.60) | (0.62) | (0.92) | |
Net Current Asset Value |
(20.12) | (18.11) | (20.41) | (22.40) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.03 | 0.03 | 0.04 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
12.47 | 15.45 | 14.03 | 13.22 | |
Average Payables |
5.23 | 4.22 | 5.05 | 5.47 | |
Average Inventory |
23.80 | 22.03 | 22.51 | 22.24 | |
Average Assets |
104.62 | 103.36 | 78.87 | 78.19 | |
Average Common Equity |
39.70 | 38.54 | 12.44 | 11.58 |
Columns are period end dates